Breaking Finance News

Zacks Investment Research downgraded Alkermes Plc (NASDAQ:ALKS) to Hold in a report released today.

Yesterday Alkermes Plc (NASDAQ:ALKS) traded 1.40% higher at $49.24. The company’s 50-day moving average is $46.78 and its 200-day moving average is $42.98. The last closing price is up 14.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 611,080 shares of Alkermes Plc traded, down from an avg. volume of 830,123

Zacks Investment Research has downgraded Alkermes Plc (NASDAQ:ALKS) to Hold in a report released on 9/27/2016.

Previously on Friday July 29, 2016, Barclays Capital reported about Alkermes Plc (NASDAQ:ALKS) raised the target price from $65.00 to $66.00. At the time, this indicated a possible upside of 0.32%.

Performance Chart

Alkermes Plc (NASDAQ:ALKS)

With a total market value of $0, Alkermes Plc has with a one year low of $27.14 and a one year high of $80.71 .

A total of 10 analysts have released a report on Alkermes Plc. Two brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 6 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $44.40.

Brief Synopsis About Alkermes Plc (NASDAQ:ALKS)

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *